Axe Compute (NASDAQ: AGPU) reported a net loss of $232.9 million for the 2025 fiscal year. The financial results follow the company's recent strategic transition from drug discovery—formerly operating as Predictive Oncology Inc.—into the highly competitive sector of GPU compute infrastructure.
The firm reported a $233M annual deficit while simultaneously securing $343.5M in new capital, signaling a aggressive shift toward hardware-heavy operations.
Financial Dislocation: The company’s balance sheet reflects the friction of a total business model overhaul, moving from biotechnology into data center assets.
Ownership Concentration: Regulatory filings from April 16, 2026, confirm that Kyle Okamoto and Okalina Ventures LLC have solidified a 4.4% stake in the company via a crypto-funded private investment in public equity (PIPE) arrangement.
Operational Context: Axe Compute currently maintains headquarters in Pittsburgh, Pennsylvania, with secondary operations in Eagan.
| Metric | Status / Value |
|---|---|
| 2025 Net Loss | $232.9 Million |
| Capital Raised | $343.5 Million |
| Primary Pivot | Bio-tech to GPU Compute |
| Major Stake | 4.4% (Okalina Ventures/K. Okamoto) |
Strategic Realignment
The transition of Axe Compute from the development of 3D cancer therapy models to GPU compute mirrors broader market trends where firms pivot to chase high-demand, supply-constrained infrastructure. Under CEO Christopher Miglino, the firm has moved to leverage crypto-linked financing to fund its "all-time high" (ATH) treasury and infrastructure build-out.
The corporate metamorphosis from a life-sciences entity to a data-intensive infrastructure provider creates a complex historical narrative. Investors now navigate a firm with the legacy baggage of a laboratory-focused company coupled with the volatile, capital-intensive requirements of modern artificial intelligence compute providers.
Read More: OtherSide Entertainment Cuts 18 More Jobs, Stops New Game Plans
